Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$10.72 +1.4%	$8.58	$4.00 ▼ $14.44	$902.38M	0.72	1.19 million shs	800,367 shs
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.76 million shs	N/A
COGT Cogent Biosciences	$7.62 +2.8%	$5.98	$3.72 ▼ $12.61	$843.68M	1.88	1.35 million shs	1.86 million shs
MNPR Monopar Therapeutics	$35.87 +2.0%	$36.12	$1.72 ▼ $54.30	$215.01M	1.01	360,767 shs	24,007 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+13.29%	+12.33%	+39.81%	+27.35%	+155.93%
CMRX Chimerix	0.00%	0.00%	0.00%	+0.12%	+890.14%
COGT Cogent Biosciences	+2.63%	+4.81%	+32.09%	+39.02%	-10.07%
MNPR Monopar Therapeutics	+4.77%	+10.15%	+17.16%	+1.65%	+876.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.7311 of 5 stars	3.7	0.0	4.7	2.0	0.8	0.6
CMRX Chimerix	0.7511 of 5 stars	1.0	0.0	4.1	0.6	1.7	0.6
COGT Cogent Biosciences	2.7792 of 5 stars	4.4	1.0	0.0	3.3	0.0	0.6
MNPR Monopar Therapeutics	3.2035 of 5 stars	3.4	5.0	0.0	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	310.45% Upside
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
COGT Cogent Biosciences	2.75	Moderate Buy	$14.43	89.48% Upside
MNPR Monopar Therapeutics	2.80	Moderate Buy	$56.50	57.51% Upside

Current Analyst Ratings Breakdown

Latest MNPR, AVXL, COGT, and CMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/29/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$21.00 ➝ $25.00
5/20/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
5/7/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)

Latest MNPR, AVXL, COGT, and CMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	6.74	6.74
CMRX Chimerix	N/A	6.33	6.33
COGT Cogent Biosciences	N/A	5.13	5.13
MNPR Monopar Therapeutics	N/A	36.91	36.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
CMRX Chimerix	45.42%
COGT Cogent Biosciences	N/A
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
CMRX Chimerix	13.10%
COGT Cogent Biosciences	7.29%
MNPR Monopar Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.64 million	Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable

MNPR, AVXL, COGT, and CMRX Headlines

Recent News About These Companies

Chardan Capital Comments on MNPR FY2025 Earnings

June 29, 2025 | americanbankingnews.com

FY2025 Earnings Forecast for MNPR Issued By Chardan Capital

June 29, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Moderate Buy" from Brokerages

June 28, 2025 | americanbankingnews.com

What is Chardan Capital's Forecast for MNPR FY2025 Earnings?

June 27, 2025 | marketbeat.com

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

June 26, 2025 | finance.yahoo.com

Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at Chardan Capital

June 24, 2025 | americanbankingnews.com

Institutional investors own a significant stake of 29% in Monopar Therapeutics Inc. (NASDAQ:MNPR)

June 23, 2025 | finance.yahoo.com

Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation

June 23, 2025 | msn.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Moderate Buy" by Brokerages

June 23, 2025 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at Chardan Capital

June 23, 2025 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Trading 0.4% Higher - Time to Buy?

June 12, 2025 | marketbeat.com

Monopar Therapeutics Inc.: Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | finanznachrichten.de

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

June 11, 2025 | zacks.com

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | globenewswire.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Down 13.8% in May

June 5, 2025 | marketbeat.com

Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%

June 3, 2025 | msn.com

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

June 3, 2025 | globenewswire.com

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 14, 2025 | manilatimes.netM

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025 | globenewswire.com

Monopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025

May 8, 2025 | nasdaq.com

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR, AVXL, COGT, and CMRX Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$10.72 +0.15 (+1.42%)

Closing price 03:48 PM Eastern

Extended Trading

$10.70 -0.02 (-0.19%)

As of 04:58 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)

As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Cogent Biosciences NASDAQ:COGT

$7.62 +0.21 (+2.77%)

Closing price 03:32 PM Eastern

Extended Trading

$7.60 -0.02 (-0.20%)

As of 04:20 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Monopar Therapeutics NASDAQ:MNPR

$35.87 +0.71 (+2.02%)

Closing price 01:04 PM Eastern

Extended Trading

$35.87 0.00 (0.00%)

As of 04:23 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time